Treatment of moderate to severe respiratory COVID-19: a cost-utility analysis

Despite COVID-19’s significant morbidity and mortality, considering cost-effectiveness of pharmacologic treatment strategies for hospitalized patients remains critical to support healthcare resource decisions within budgetary constraints. As such, we calculated the cost-effectiveness of using remdes...

Descripción completa

Detalles Bibliográficos
Autores principales: Congly, Stephen E., Varughese, Rhea A., Brown, Crystal E., Clement, Fiona M., Saxinger, Lynora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423816/
https://www.ncbi.nlm.nih.gov/pubmed/34493774
http://dx.doi.org/10.1038/s41598-021-97259-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423816/
https://www.ncbi.nlm.nih.gov/pubmed/34493774
http://dx.doi.org/10.1038/s41598-021-97259-7

Ejemplares similares